Primary Membranous Nephropathy (PMN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Primary Membranous Nephropathy (PMN) Market Outlook

Thelansis’s “Primary Membranous Nephropathy (PMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary membranous nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Membranous Nephropathy (PMN) Overview

Membranous Nephropathy (MN), also called membranous glomerulopathy, is a type of glomerular disease resulting in nephrotic syndrome. It is defined by the presence of significant proteinuria (>3.5 g/day) and the manifestation of clinical symptoms such as peripheral edema, hypertension, frothy urine, and thromboembolic events. MN can be classified into primary (75-80%) and secondary (20-25%) forms. Primary MN is often idiopathic but may be associated with antibodies against the phospholipase A2 receptor (PLA2R) antigen (70-80%), neural epidermal growth factor-like 1 (NELL) (15-20%), thrombospondin (1-5%), neutral endopeptidase (NEP), or exostosin (EXT1/EXT2). Secondary MN is linked to infections, neoplasms, drugs, heavy metal poisoning, autoimmune diseases, and other miscellaneous factors. The formation of antigen-antibody complexes between the glomerular basement membrane and podocytes causes MN. These complexes, which primarily consist of immunoglobulin IgG4, complement C3, and C5b-C9 membrane attack complexes (MAC), activate the complement system and generate proteases, cytokines, and oxidants that result in cellular and tissue damage, leading to proteinuria. MN must be differentiated from other nephrotic syndromes that present with similar symptoms. Some differential diagnoses for MN include focal segmental glomerulosclerosis, minimal change disease, diabetic nephropathy, IgA nephropathy, and membranoproliferative glomerulonephritis. The management of MN involves symptomatic treatment with diuretics, statins, angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), systemic anticoagulant therapy, antihypertensives, and dietary salt restriction. Approximately one-third of patients will respond to these conservative measures, while another one-third will require additional treatments.

• The estimated incidence of membranous nephropathy in the USA is 12 cases per one million individuals. MN is less common in children and is primarily due to secondary causes.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: